Systemic therapy for melanoma.
Advanced melanoma is a disease with a poor prognosis. Most of the currently available chemotherapy agents are ineffective. In contrast to other cancers, immune-based and novel, targeted therapies appear to have some effect in melanoma. Exciting research in the past few years holds hope for the future. We provide an overview of the current management principles of this condition with special emphasis on the emerging options in the systemic therapy of advanced disease.
Ganesan
Prasanth
P
Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India.
Bakhshi
Sameer
S
D015703:Antigens, CD / Q000276:immunology; D060908:CTLA-4 Antigen; D006801:Humans; D016219:Immunotherapy, Adoptive; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D008545:Melanoma / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis
D015703:Antigens, CD; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D007376:Interleukin-2; D007372:Interferons